Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463813 | 1.00 | SCN9A (0.47) | SCN9ATHRBSCN7AKCNH2SCN5A | |
| SCHEMBL18638558 | 1.00 | SCN9A (0.47) | SCN9ATHRBSCN7AKCNH2SCN5A | |
| SCHEMBL29463872 | 1.00 | SCN9A (0.47) | SCN9ATHRBSCN7AKCNH2SCN5A | |
| SCHEMBL22227596 | 1.00 | SCN9A (0.47) | SCN9ATHRBSCN7AKCNH2SCN5A | |
| SCHEMBL18751931 | 0.86 | PPARG (0.41) | SCN9A | |
| SCHEMBL18751929 | 0.86 | PPARG (0.41) | SCN9A | |
| SCHEMBL29463828 | 0.80 | SCN9A (0.52) | SCN9ASCN7AKCNH2SCN5AMAPK1 | |
| SCHEMBL18638520 | 0.80 | SCN9A (0.52) | SCN9ASCN7AKCNH2SCN5AMAPK1 | |
| SCHEMBL29463817 | 0.78 | SCN9A (0.54) | SCN9ASCN7AKCNH2SCN5AMAPK1 | |
| SCHEMBL18638315 | 0.78 | SCN9A (0.54) | SCN9ASCN7AKCNH2SCN5AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3348547-B1 | BENZIMIDAZOLE DERIVATIVES AS NAV 1.7 (SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT (SCN9A)) INHIBITORS FOR TREATING PAIN, DYSURIA AND MULTIPLE SCLEROSIS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2020-07-22 | — | — | EP | claimed |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-09-10 | — | — | US | claimed |
| EP-3348547-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE OF SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2018-07-18 | — | — | EP | claimed |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2018-06-21 | — | — | US | claimed |
| US-9688670-B2 | Benzimidazole compounds and medical uses thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-06-27 | — | — | US | claimed |
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2017-04-20 | — | — | US | claimed |
| EP-3348547-B1 | BENZIMIDAZOLE DERIVATIVES AS NAV 1.7 (SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT (SCN9A)) INHIBITORS FOR TREATING PAIN, DYSURIA AND MULTIPLE SCLEROSIS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3348547-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE OF SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2018-07-18 | — | — | EP | disclosed |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-9688670-B2 | Benzimidazole compounds and medical uses thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-9688670-B2 | Benzimidazole compounds and medical uses thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | KCNA7, SCN1A, KCNA1 | SCN9A 60/4885THRB 2034/4885SCN7A 18/4885 |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SCN1B, SCN1A, KCNA7 | SCN9A 64/4885THRB 1968/4885SCN7A 17/4885 |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | KCNA7, SCN1A, KCNA1 | SCN9A 60/4885THRB 2034/4885SCN7A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.